Audit and screening study to determine the prevalence of peripheral arterial disease. A cross-sectional multi-centre clinical study in subjects with cardiovascular disease risk factors.
Peripheral Arterial Disease
45 Years +
Endpoint Classification: N/A
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Pretium Pty Ltd
No locations available
|Other: All Subjects|
ABI Screening Test Population: Subjects of either sex, any race, with at least two of the specified CVD risk factors, with no overt cardiovascular disease.
Procedure/Surgery: Ankle-brachial index (ABI) Screening Test
Patients will undergo an ABI measurement